Oncology · Small Cell Lung CancerTrial Updateclinicalmid-term

Phase I/II Trial of Iadademstat with Atezolizumab or Durvalumab in Extensive Stage Small Cell Lung Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:32:38 PM

Assessment confidence: 81% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of iadademstat in combination with atezolizumab or durvalumab could significantly alter treatment paradigms for extensive stage small cell lung cancer. Successful outcomes may enhance competitive positioning and broaden therapeutic options in a challenging oncology market. Regulatory context from FDA (FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer) supports the near-term read. Assessment grounded in 15 ranked evidence items (13 high-relevance).

Strategic Assessment

The strongest clinical anchor is A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (io ). In lung cancer, 1 regulatory and 4 competitive items passed relevance filtering for atezolizumab. If the trial demonstrates improved efficacy, it could lead to increased market share for the combination therapy, potentially impacting revenue streams for the involved companies.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (roche). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. If successful, this combination could enhance treatment options against existing therapies, impacting market dynamics for lung cancer treatments.

Regulatory Outlook

Regulatory risk is concentrated around FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer (FDA). Sub-indication match (lung cancer). Positive trial results may prompt expedited regulatory filings, influencing approval timelines and market entry strategies for the combination therapy.

Key Risks

Elevated medium regulatory exposure for atezolizumab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates improved efficacy, it could lead to increased market share for the combination therapy, potentially impacting revenue streams for the involved companies.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Upside for atezolizumab may improve if A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PAR (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Neuroendocrine Carcinomas · Trial Update · If successful, this combination could position atezolizumab as a key treatment option in a niche cancer market, potentially impacting competitors focused on neuroendocrine tumors.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety data, as well as any subsequent regulatory filings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (IO )
FDA document
View source
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PAR
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Testing Osimertinib as Treatment for Lung Cancers With an EGFR Exon 20 Change
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
CAFs Enhance Adenosine Production in NSCLC, Impeding T Cell Response
Humanexa Signalsmedium relevance
Sub-indication match (lung cancer)
Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas
Humanexa Signalsmedium relevance
Entity match (atezolizumab)
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Can
Bristol Myers Squibblow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Virtual screening and experimental validation of METTL3-targeting peptide with in vitro antiproliferative activity against non-small cell lung cancer cells.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Microwave hyperthermia enhances radiosensitivity of highly invasive non-small cell lung cancer cells via inhibiting Sonic Hedgehog signaling pathway.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
AI-guided data-driven kinetic modelling carbon quantum dot-enabled pH-responsive CMC/CeO(2) nanocarriers for quercetin delivery and in vitro evaluation in lung cancer cells.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

atezolizumab
durvalumab

Commercial impact

medium

If the trial demonstrates improved efficacy, it could lead to increased market share for the combination therapy, potentially impacting revenue streams for the involved companies.

Regulatory impact

medium

Positive trial results may prompt expedited regulatory filings, influencing approval timelines and market entry strategies for the combination therapy.

What to watch

Monitor trial results for efficacy and safety data, as well as any subsequent regulatory filings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.